詢 價
索取COA
產品描述
產品數據庫
I. Background | |||||||||||||||||||||||||||||||||||
Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials.
計算數據下載:DC198N0162.tmb |
|||||||||||||||||||||||||||||||||||